Phase 1 Muscular Dystrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a genetically confirmed diagnosis of facioscapulohumeral muscular dystrophy (FSHD) type 1 or type 2, or a clinical diagnosis of FSHD type 1 with a close biological relative (parent, sibling, or child) who has a confirmed genetic mutation for the condition
- People aged between 18 and 75 years old
- People whose condition falls within a specific clinical severity range, scored between 0 and 10 on a standard FSHD scale (confirm with trial site)
- People who are able to walk 30 feet (approximately 9 metres) without physical assistance from another person
- People who have measurable muscle strength against gravity in at least one of the muscles at the front of the lower leg, or who have a suitable leg muscle identified by MRI for a needle biopsy procedure
- People who are willing and able to give their informed consent to take part
- People who agree to follow the contraceptive requirements set out by the trial for its entire duration
Who may not be able to join:
- People who are pregnant or who plan to become pregnant during the trial
- People who have a poorly controlled medical condition
- People who have taken part in a study of an experimental treatment within 3 months before enrolling
- People who are currently taking beta-blockers, anabolic agents (such as muscle-building medications), or potassium-wasting diuretics (a type of fluid tablet)
- People who are currently taking or plan to take a GLP-1 agonist medication (a type of drug used for diabetes or weight management) during the trial
- People who have any condition or health reason that would interfere with testing or prevent the use of a type of medication called a beta-agonist (confirm with trial site)
- People who are taking blood-thinning medications or any other medications that would make a needle muscle biopsy unsafe
- People who have a condition that causes problems with processing lactose or certain sugars, such as galactosaemia, lactase deficiency, or glucose-galactose malabsorption (people with general lactose intolerance may still be considered, at the discretion of the principal investigator)
- People who are taking any medications or therapies that are not compatible with Clenbuterol, the study drug being investigated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 9139459936
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Clenbuterol-related adverse reactions; change in heart rate; change in blood pressure; Safety Lab Potassium (K); Safety Lab Glucose; Tolerability of 3 doses of clenbuterol in sequential cohorts; Safety ECG; Safety Lab Creatine kinase (CK)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.